Date: 2015-06-09
Type of information: Development agreement
Compound: targeted therapeutic peptide
Company: PEP Therapy (France) CleveXel Pharma (France)
Therapeutic area: Cancer - Oncology
Type agreement: developement
Action mechanism: peptide. The CP&IP ( cell-penetrating and interfering peptide) platform is used as a shuttle to deliver drugs into the cell. These short interfering peptides are designed to specifically block relevant protein/protein interactions, thus inhibiting pathological mechanisms. This drug candidate targets an interaction between two intracellular proteins, Caspase-9 and PP2A. It has been validated on preclinical models that are highly-representative of tumors observed in humans (patient-derived xenograft or PDX models), showing targeted efficacy on cancer cells and an absence of toxicity, especially in triple-negative breast cancer and ovarian cancer.
Disease:
Details: * On June 9, 2015, PEP Therapy and CleveXel Pharma announced the launch of the codevelopment of a peptide as a targeted therapy in oncology. This product aims to treat cancers with a high medical need. It is based on an innovative technology involving bifunctional peptides that penetrate cells, then specifically block pathological mechanisms without affecting physiological mechanisms (Cell Penetrating & Interfering Peptides (CP&IP) technology). This partnership will take the product through to its clinical proof of concept. The start of the regulatory preclinical phase is scheduled for the end of 2015 with a view to beginning clinical trials at the end of 2016.
CleveXel Pharma will help PEP Therapy to accelerate the development of its first candidate. PEP Therapy and CleveXel Pharma’s mutual goal is to take the product through to its clinical proof of concept with the risks, costs and benefits being shared. Simultaneously, PEP-Therapy will continue the development of companion biomarkers for foreseeing the effectiveness of the product, opening the way for personalized and optimized use of this treatment in oncology.
Financial terms:
Latest news:
